Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 460

4.

Sarcoma cells engineered to secrete IFN-gamma or IL-2 acquire sensitization to immune cell killing via different mechanisms.

Flemming CL, Patel PM, Box G, Eccles SA, Collins MK.

Cytokine. 1997 May;9(5):328-32.

PMID:
9195131
5.

Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).

Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R.

Clin Ter. 2006 Jul-Aug;157(4):377-86. Review. Retraction in: Clin Ter. 2008 May-Jun;159(3):207.

PMID:
17051976
6.

Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.

Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.

Cancer Res. 2000 Sep 1;60(17):4838-44.

7.
8.

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.

Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E.

J Immunol. 1994 Mar 1;152(5):2324-32.

PMID:
7907636
10.

Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.

11.

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.

Comes A, Rosso O, Orengo AM, Di Carlo E, Sorrentino C, Meazza R, Piazza T, Valzasina B, Nanni P, Colombo MP, Ferrini S.

J Immunol. 2006 Feb 1;176(3):1750-8.

12.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
14.

IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules.

Kubota A, Lian RH, Lohwasser S, Salcedo M, Takei F.

J Immunol. 1999 Dec 15;163(12):6488-93.

15.

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.

Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S.

J Immunol. 2004 Feb 1;172(3):1540-7.

16.

Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.

Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP.

Cancer Res. 2002 Aug 1;62(15):4390-7.

17.

Target cell induced activation of NK cells in vitro: cytokine production and enhancement of cytotoxic function.

Das S, Varalakshmi C, Kumari AL, Patel M, Khar A.

Cancer Immunol Immunother. 2001 Oct;50(8):428-36.

PMID:
11726137
19.
20.

Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Kemp RA, Ronchese F.

J Immunol. 2001 Dec 1;167(11):6497-502.

Items per page

Supplemental Content

Write to the Help Desk